This study aimed to investigate predictors of baseline, 4-month, and change scores of pain intensity in breast cancer survivors on aromatase inhibitors.<h4>Methods</h4>Multiple regression analyses using intent-to-treat data (<i>N</i> = 110; mean age 56.2 ± 7.7 years) were performed to identify possible predictors applying a biopsychosocial approach with five domains: sociodemographic characteristics, treatment-related factors, health-related factors, physical function factors, and group allocation. Here, CYP19A1 is linked to breast carcinoma.